Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Aug 1, 2022
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aprea Therapeutics, Inc.
| 24.3K |
—
|
—
| +113.22% | 45.76K | +1 |
Jul 28
| ||||||
Aprea Therapeutics, Inc.
| -8.39K |
$0.81 | -$6,753.95 | -28.11% | 21.46K | +1 |
Jun 3
| ||||||
Aprea Therapeutics, Inc.
| 14.01K |
$1.82 | -$3,619.98 | +88.45% | 29.85K | +1 |
Mar 10
| ||||||
Aprea Therapeutics, Inc.
| -1.33K |
$1.74 | -$2,307.24 | -7.72% | 15.84K | +1 |
Feb 25
| ||||||
Aprea Therapeutics, Inc.
|
0
|
$2.44 | -$83,600.00 |
—
| 17.17K | +1 |
Dec 1
|
Scheduled
| |||||
Aprea Therapeutics, Inc.
|
0
|
$2.96 | -$112,200.00 |
—
| 17.17K | +1 |
Nov 1
|
Scheduled
| |||||
Aprea Therapeutics, Inc.
|
0
|
$2.91 | -$109,175.00 |
—
| 17.17K | +1 |
Oct 1
|
Scheduled
| |||||
Aprea Therapeutics, Inc.
| -5.46K |
$2.95 | -$138,565.80 | -24.13% | 17.17K | +1 |
Sep 20
|
Scheduled
| |||||
Aprea Therapeutics, Inc.
| -1.72K |
$4.59 | -$7,913.16 | -7.08% | 22.63K |
Sep 10
| |||||||
Aprea Therapeutics, Inc.
| -1.15K |
$3.98 | -$4,573.02 | -4.51% | 24.35K |
Aug 25
| |||||||
Aprea Therapeutics, Inc.
| 15K |
—
|
—
| +142.86% | 25.5K |
Mar 10
| |||||||
Aprea Therapeutics, Inc.
| 10K |
—
|
—
| +2,000.00% | 10.5K |
Feb 25
| |||||||
Aprea Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Mar 24
| |||||||
Aprea Therapeutics, Inc.
| 500 |
$15.00 | $7,500.00 |
∞
| 500 |
Oct 7
| |||||||
Aprea Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||